



THERAVECTYS CLOSES 5,5 M FUNDING ROUND

This new financing round will enable THERAVECTYS to enrich its products portfolio and address a wide range of indications in infectious diseases and oncology.

PARIS, APRIL 18, 2017 – THERAVECTYS, a vaccine company that designs T-cell vaccines based on its proprietary lentiviral vector platform, is pleased to announce the closing of a 5,5M funding round.

This funding round was financed by a group of existing shareholders to support the strategic development of a broader pipeline for the company. Theravectys will leverage its core capacities for early development and preclinical proof-of-concept studies and expand its asset portfolio with chronic infections therapeutic vaccines such as MDR Tuberculosis or Hepatitis B, new prophylactic vaccines for tropical diseases including Zika and Malaria, as well as cancer vaccines (Melanoma, Bladder, HPV-induced cancers...).

“The strategic plan presented to shareholders in late 2016 and its perspective to develop an extensive portfolio from the company’s IP, closely teaming up with Pasteur Institute, has convinced me to further invest in Theravectys,” says Roger Burger, Investment Manager at FGP Capital Private Equity. “We want to make the benefits of the technology available to the most and with our long-standing experience, our platform has reached the maturity needed to deliver results in all these indications.”

“Our greatest strength lies in our discovery and early development expertise,” adds Dr. Pierre Charneau, Founder of Theravectys, and inventor of lentiviral vectors. “It makes most sense to focus our efforts and bring on strategic partners with the relevant clinical capacities to move our products further towards market”.

With the renewed trust of its shareholders, the company will move relentlessly through its planned proof-of-concept studies for the next two years and will attract many long-term and successful strategic alliances.

About THERAVECTYS

THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the [Pasteur Institute](#), Theravectys leverages its [proprietary platform](#) to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Our purpose: ‘profoundly transform global health’. Our approach: strategic industrial partnering for leading our [PoC-validated vaccine-candidates](#) to clinical trials and to market.

For more information

+33 43 90 19 20

contact@theravectys.com

